									<u> </u>
	LIST OF REFERENCE(S) CITED ATTY, DOCKET N R0056B-R								0
Corrected Form 1449 - originally filed 4/14/00 APPLICANT(S) DANI							KWARDT, et al.		
FILING DATE 10-DEC-1999							GROU	P :	0/07
			U.S. P	ATENT DOC	JMENTS			•	JC
Exam Initial	Ref.	# Document #	Date	Name		Class/ Subclass		Filing Date	
				<u> </u>					
							_		
FOREIGN PATENT DOCUMENTS									
	Ref#	Document #	Date	Coun	try; Assignee)	Trans		slation	
						Y	'es	No	
0	B-1	ABSTRACT of FR 2762315-A1	22-Apr-1997	France; Laboratoires Logeais SA Jacques				patent in French	
					PCT Application 63, dated Oct 29-				
	B-2	WO98/22494-A2	28-May-1998		PCT Application; Athena Neurosciences, Inc.		glish		
	B-3	WO97/43251-A1	20-Nov-1997	PCT Applic S.P.A.	ation; Italfarmaco	in En	glish	l	
	B-4	Abstract of WO97/49679-A1	31-Dec-1997	PCT Application Pharmaceu	ation; Ono tical Co., Ltd.			patent in Japanes	
	B-5	Abstract of WO98/15525-A1	16-Apr-1998	PCT Application	ation; Sumitomo ticals, Co. Ltd.			patent in Japanes	
V	B-6	EP 0 084941-A1	03-Aug-1983	European A Imperial Ch PLC	pplication; emical Industries	in Eng	glish		
X	B-7	Abstract of JP 08311096 A2	26-Nov-1996	Japanese A Ltd.	pplication; Teijin	*		patent in Japanese	

9

LIST OF REFERENCE(S) CITED				ATTY. DOCKET I R0056B-F		SERIAL NO. 0 9/459,20 1		
Corrected Form 1449 - Previously mailed to Patent Office APPLICANT(on June 26, 2000					APPLICANT(S) DAN	ANKWARDT, et al.		
Supplemental IDS					FILING DATE 10-DEC-199	GROUP 1653		
			U.S.	PATENT DOC	UMENTS			
Exam Initial	Ref. #	Document #	Date		Name	Class/ Subclass	Filing Date	
			FOREIG	N PATENT DO	CUMENTS	400		
	Ref.#	Document #	Date	Country; As	ssignee	Tra	anslation	
			<u> </u>			Yes	No	
B-8		WO 95/12612	11-May-1995	Lambert Co	Application; Warner in Englishert Company			
	B-9	WO 92/22523	23-Dec-1992	PCT Application Corporation Inc.	ation; Research Technologies,	in English		
	B-10	WO 96/33176	24-Oct-1996	PCT Application Pont Merck Co.	ation; The Du Pharmaceutical	in English		
	B-11	WO 98/55449	10-Dec-1998	PCT Applica University of	ation; The f Queensland	in English		
V	B-12	Derwent Abstract of JP 09 025293	28-Jan-1997	Japan; Teiji	in Ltd.		patent in Japanese	
X	B-13	Derwent Abstract of JP 01 146896	08-Jun-1989	Japan; Fuji KK	Yakuhin Kogyo		patent in Japanese	
KAMINI	X	will	Hay		ATE CONSIDERED	-04		
AMINE ation if	R: Initial	if reference consid	ered, whether or no	t citation is in co	onformance with MF m with next commu	PEP 609; Drav	v line through	



LIST OF REFERENCE(S) CITED					ATTY. DOCKET NO. R0056B-REG		SERIAL NO. 09/459,201	
Supplem	iental IDS	filed 4/4/01	APPLICANT(S) DANKWARDT, et al.					
			FILING DATE 10-DEC-1999	GROUP		P 1646		
			U.S. PA	TENT DOC	JMENTS			
Exam Initial	Ref.#	Document #	Date	Name		Class/ Subclass		Filing Date
FOREIGN PATENT DOCUMENTS								
	Ref.#	Document #	Date	Country; Assignee		Tran		nslation
							Yes	No
X	B-13	WO 97/05865	20-Feb-1997	PCT Applic	in Er	nglish		
\times	B-14	JP 09 025293	28-Jan-1997	Japanese Patent, Teijin Ltd No Japane				Japanese
DL	B-15	CAS abstract and list of compounds to JP 09 025293	28-Jan-1997	Teijin, Ltd	in Er	nglish		
OTHER DOCUMENTS								
C-7 Fertala, et al., <u>J. Bio. Chem.</u> Vol. 269, pp 11584-11589 (1994), Self-assembly into Fibrils of Collagen II by Enzymic Cleavage of Recombinant Collagen II.								
EXAMINER DATE CONSIDERED 9/8/09								
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

				-5G					
	L	IST OF REFERENCE(S) CITED	ATTY. DOCKET NO. R0056B-REG	SERIAL NO. 09/459,20 10					
			APPLICANT(S) DANKWARDT, et al.						
			FILING DATE 10-DEC-1999	GROUP 1646					
		OTHER I	DOCUMENTS						
H	C-1	Ewenson, et al., <u>Eur. J. Med. Chem.</u> Vol. 2: of peptide hydroxamate inhibitors of degrad	7:3, pp 179-186 (1992), Synthesi lation of substance P analogues"	s and biological activity					
	C-2	Chen, et al., <u>Bioorg. Med. Chem. Lett.</u> , Vol. 2:12, pp1685-90 (1992), "One-pot synthesis of cathepsin inhibitors: N ^{α-} protected N-peptidyl-o-acetyl hydroxylamines catalysed by alcalase followed by lipase in anhydrous t-butanol"							
	C-3	Nikam, et al., <u>Tetrahedron Letters</u> , Vol. 36:2, pp 197-200 (1995), "Synthesis of hydroxamic acid Pd/BaSO4 as a new catalyst for the deprotection of o-benzyl hydroxamates"							
	C-4	Laufer, et al., <u>Eur. Journal of Biochemistry</u> , Vol. 150:1 pp 135-140 (1985), "Inhibition of substance P degradation in rat brain preparations by peptide hydroxamic acids"							
*	C-5	Fischer, et al., <u>Pharmazie</u> , Vol. 38:4, pp 249-250 (1983), "N,O-Diacylhydroxylamines as Enzyme-Activated Inhibitors for Serine Proteases"							
DL	C-6	Hoffmann, et al., <u>Journal of Organic Chemistry;</u> Vol. 29: pp 748-751 (1964), "A Peptide Synthesis via Hydroxamic Acids"							
		1							
EXAMINI	ER	D.	ATE CONSIDERED $Q = Q = I$	n 4					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.